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Abstract
Purpose: We report the first cervical cancer cases treated with interstitial electronic
brachytherapy (eBT) at our hospital and compare them with plans made with high‐
dose‐rate interstitial brachytherapy based on Ir192 (HDR‐BT).
Materials and methods: Eight patients with cervical cancer were treated with the
Axxent eBT device (Xoft, Inc.). Planning was with magnetic resonance imaging and
computed tomography following the recommendations of the EMBRACE protocol.
The dosimetry parameters of organs at risk (OAR) were evaluated for the bladder,
rectum, and sigmoid colon (D2cc, D1cc, and D0.1cc). In addition, the V150 and
V200 of irradiated tissue were compared for both eBT and HDR‐BT. All patients
received intensity‐modulated external beam radiation therapy with a regimen of 23
sessions of 2 Gy followed by four sessions of 7 Gy of eBT performed over 2 weeks
(two sessions followed by another two sessions a week later) following the
EMBRACE recommendations. Each of the eight patients was followed to assess
acute toxicity associated with treatment.
Results: The doses reaching OAR for eBT plans were lower than for HDR‐BT plans.
As for acute toxicity associated with eBT, very few cases of mucositis were
detected. No cases of rectal toxicity and one case with grade 1 urinary toxicity were
detected. The results at 1 month are equally good, and no relapses have occurred to
date.
Conclusions: The first results of treatment with the Axxent eBT device are promis-
ing, as no recurrences have been observed and toxicity is very low. eBT is a good
alternative for treating cervical cancer in centers without access to conventional
HDR.
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1 | INTRODUCTION
Cervical cancer is the second most frequent type of cancer in
women, with a mean age at onset of 45 yr worldwide. It is also the
most frequent type of cancer in developing countries, with more
than 500,000 new cases diagnosed every year.1
The initial approach in patients with stage IA1‐IA2 cervical cancer
is generally surgery, if possible, and radiotherapy or brachytherapy
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(BT) if not. Patients with advanced cancer (IB2‐IIA bulky‐IIB‐III‐IVA)
receive chemotherapy and radiotherapy concomitantly, as well as BT,
irrespective of whether they can undergo surgery.2
The use of BT as a key component in the treatment of cervical
cancer is the main prognostic factor in local control of the disease.3
As with cancer at other sites, the response of gynecological can-
cer to radiation is dose‐dependent, with improved local control at
higher doses.4 Better knowledge of tumor extension at diagnosis
and the response to the treatment received has led to more realistic
local treatment of cervical carcinoma, with adapted BT that is tai-
lored depending on the findings at different points during the course
of the disease. Therefore, BT has proven to be efficacious as a com-
ponent of radiation therapy. The dose released by BT in contact
with the tumor (4 fractions in 2 weeks) is at least equivalent to the
dose administered during external beam radiation therapy (EBRT) on
the pelvis for 5 or 6 weeks.5
Any nonsurgical treatment of gynecologic cancer with curative
intent should combine EBRT and BT.6 The traditional approach has
been low‐dose rate BT.7 For the last few years, the type of BT
applied has been high‐dose rate BT (HDR‐BT) with Ir192,8 which
makes it possible to optimize both the dose and patient comfort,
since it can be administered on an outpatient basis, even though
more sessions are necessary.
Technical advances in imaging and dosimetry have led to the use
of computed tomography (CT) and magnetic resonance imaging
(MRI) to locate the tumor and organs at risk (OAR) and to plan treat-
ment based on real anatomy.9
A working group from GEC‐ESTRO published recommendations
on contouring the target tumor and OAR, as well as on the dose vol-
ume parameters to be reported for image‐guided BT in definitive
radiotherapy for locally advanced cervical cancer.10 The major advan-
tage of this technique is the possibility of conforming the dose to
both volume (3D) and time (4D). Thus, repetitive imaging performed
before each BT implant makes it possible to adapt the BT dose to
the anatomy of the individual patient, taking into account not only
the position of the OAR but also tumor regression, which is often
achieved with previous EBRT and chemotherapy.
The EMBRACE study,11 which was developed some time after
publication of the GEC‐ESTRO recommendations, attempted to unify
all of the processes involved in the management of cervical cancer
by providing guidelines for the participating centers. A key feature is
the use of MRI to better define the tumor and the OAR volumes. It
allows to prescribe higher doses to the region of interest thus
increasing the tumor control as shown in the Retro EMBRACE
study.12 All of the participating centers used HDR‐BT with Ir192 in
their treatments.
Electronic brachytherapy (eBT) has been evolving since the start
of the 21st century13 and has become a treatment option for various
tumor sites in different settings.14–18
The Axxent eBT unit (Xoft, Inc., subsidiary of iCAD, San José,
CA, USA) provides treatment to patients with a miniature 50‐kVp x‐
ray source that irradiates the tumor directly in skin cancer and with
different applicators in the case of breast or gynecologic cancer.
The unit is constructed of a disposable mini‐x‐ray tube inserted
into a flexible plastic sheath approximately 5.5 mm in diameter. Water
is pumped around the source to reduce heating from the target. The
electrons (20–50 keV) are emitted from a filament nearly 1 cm from
the anode. The anode is made mainly of a microlayer of tungsten on
an yttrium substrate that acts as a buffering layer and a small amount
of silver that acts as a constituent of the brazing alloy. The anode tran-
sitions are from a spherical tip to a conical‐hemisphere section and
finally to a cylinder. The source is mounted on a mechanical robot arm
that is attached to a movable treatment control console.19
The unit can be used to treat nonmelanoma skin tumors, intraop-
erative radiotherapy in breast cancer, and postoperative treatment
of endometrial and cervical cancer.
The case of skin tumors is problematic. High doses can reach
bone (high atomic number), owing to the predominant photoelectric
effect at low energies.20 Such a situation could arise in cases of cer-
vical cancer, although, to date, we have had no reports of this prob-
lem at our center.
It can also be used to treat cervical cancer in protocols that
require treatment with HDR‐BT after chemotherapy and EBRT with
a dedicated applicator (Fig. 1).
The eBT system at our center was acquired in May 2015 for
treatment of skin cancer and intraoperative radiotherapy for breast
cancer after tumor removal.
Postoperative treatment of endometrial cancer with the Axxent
eBT unit was started in 2015, and in May 2016, we treated the first
case of cervical cancer.
This therapeutic approach was traditionally applied in many cen-
ters throughout the world with HDR devices based on Iridium‐192
(Ir192, half‐life of 73.8 days and mean energy of 0.355 MeV) and
different types of applicator, of which Fletcher applicators were the
most common. In the current century, others have appeared and
may help in treatment based on interstitial needles placed in various
configurations.21
Retrospective studies on patients treated with Ir192 have com-
pared endometrial cancer,22,23 cervical cancer,24 and breast cancer.25
A lower dose was always found in the OAR in patients whose planning
was based on eBT, although the patients in those studies were treated
with Ir192. Another study comparing patients with endometrial cancer
treated with eBT has reported favorable preliminary results.26
The objective of treatmenting with eBT is to provide an alternative
with a portable device, thus conferring the advantage of mobility and
obviating the need for a shielded room: with the energy used by the
device, screening equivalent to 0.5 mm of lead on walls and doors is
sufficient. Transport is no longer a factor since it does not involve
radioactive sources. In addition, the device facilitates quality control
and preparation and implementation of the treatment.27
2 | MATERIALS AND METHODS
At our center, patients diagnosed with cervical cancer who are can-
didates for eBT after EBRT are selected from among those who, at
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F I G . 1 . Cervical applicator.
TAB L E 1 Characteristics of electronic brachytherapy sources.
Working life of eBT sources
750 minutes
of clinical use
Deviation allowed with respect to
calibration certificate
<10%
Deviation allowed with respect
to first measure
<5%
Maximum energy 50 kVp
Average energy 29.6 keV
Treatment time for cervical treatment 15–25 min
TAB L E 2 Patients and treatments characteristics.
Patients 8
Age + Range (years) 59.7 (27–72)
FIGO Stage %
IB1 12.5% (1)
IB2 12.5% (1)
IIA2 25% (2)
IIB 37.5% (3)
IIIB 12.5% (1)
Uterine probe inclination 15° (8)
Ovoids 3 cm 50% (4)
Ovoids 2.5 cm 25% (2)
Ovoids 2 cm 25% (2)
Time IMRT to eBT 10.6 (7–15) days
OTT 52.5 (49–58) days
Treatment time in tandem per fraction 14.6 (8.8–19.5) min
Treatment time in ovoids per fraction 3.5 (0.8–7.5) min
Proportions are given with number of total and median range.
FIGO stage is given in percentage of the total number of patients.
Time IMRT to eBT: time between the end IMRT treatment and the start
of eBT.
OTT, Overall treatment time.
TAB L E 3 EMBRACE protocol dosimetric requirements based on
ESTRO‐ABS recommendations for CTVs and OARs in EQD2.
Target
D90 HR‐CTV
EQD210
D98 HR‐CTV
EQD210
D98 IR‐CTV
EQD210
planning aims >90 Gy < 95 Gy >75 Gy >60 Gy
Limits for
prescribed dose
>85 Gy
OAR Bladder D2cc
EQD23
Rectum D2cc
EQD23
Sigmoid D2cc
EQD23
Planning aims <80 Gy <65 Gy <70 Gy
Limits for
prescribed dose
<90 Gy <75 Gy <75 Gy
TAB L E 4 EMBRACE protocol dosimetric requirements for BT (4
fractions of 7 Gy) after 46 Gy of EBRT in EQD2, %PD and dose per
BT fraction.
D90 HR‐CTV D98 HR‐CTV
%PD 1 fraction %PD 1 fraction
>107% >7.5 Gy >80% >5.6 Gy
<117% <8.2 Gy
D98 IR‐CTV
%PD 1 fraction
>46% >3.2 Gy
Bladder: D2cc ≤ 90 Gy, D0.1cc ≤ 110‐115 GyBladder: D2cc ≤ 75–
87%, D0.1 cc ≤ 107–113%Bladder: D2cc ≤ 5.3–6.1 Gy,
D0.1cc ≤ 7.5–7.9 Gy
Rectum: D2cc ≤ 75 Gy, D0.1 cc ≤ 80–85 GyRectum: D2cc ≤ 51–67%,
D0.1 cc ≤ 75–81%Rectum: D2cc ≤ 3.6–4.7 Gy, D0.1 cc ≤ 5.3–5.7 Gy
Sigmoid: D2cc ≤ 75 Gy, D0.1 cc ≤ 80–85 GySigmoid: D2cc ≤ 60–
67%, D0.1 cc ≤ 75–81%Sigmoid: D2cc ≤ 4.2–4.7 Gy, D0.1 cc ≤ 5.3–
5.7 Gy
Prescribed dose of BT treatment: 4 fractions of 7 Gy.
EQD2n, Dosage equivalent to 2 Gy per session for α/β = n according to
the quadratic linear model. The limit value is the result of adding EBRT +
BT; HR‐CTV, High‐risk clinical target volume; IR‐CTV, Intermediate‐risk
clinical target volume; %PD, Percentage of prescribed dose.
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their first evaluation for radiotherapy, are expected to have a resid-
ual tumor ≤3 cm with no parametrial involvement after EBRT. They
are re‐evaluated after EBRT to determine whether the diagnostic
parameters remain unchanged (see above).
In this study eight patients were treated using the Axxent (Xoft)
device between May 2016 and June 2018 with the Axxent cervical
applicator (Modified Henschke HDR Cervix Applicator‐Fig. 1),
intrauterine probes angled at 15°, and ovoids of 2–3 cm. After
excluding quality control time, each eBT source has a useful average
clinical life of 750 min. If a source is not stable, it is withdrawn and
replaced (Table 1). Each session lasted between 15 and 25 min.
Mean age was 59.8 yr (27–70 yr), with different tumor stages
(Table 2). The eight patients received chemotherapy without surgery
and adjuvant EBRT in the form of intensity modulated radiation
therapy (IMRT) with a regimen comprising 23 sessions of 2 Gy each
all over the pelvis, followed by eBT (28 Gy in four sessions). The
F I G . 2 . Isodose lines in Axial, Coronal,
and Sagittal views for eBT and Ir192. (a)
Axial view: Distances to 25% of the
prescribed dose: 5.1 cm (eBT) and 5.7 cm
(Ir192). (b) Coronal view: Distances to 25%
of the prescribed dose: 5.9 cm (eBT) cm
and 6.2 cm (Ir192). (c) Sagittal view:
Distances to 25% of the prescribed dose:
5.2 cm (eBT) cm and 5.7 cm (Ir192). Red
line: HR‐CTV contour. Prescribed Dose:
7 Gy per fraction.
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sessions were administered twice weekly (Thursday and Friday) after
radiation therapy. Planning was with MRI and CT scans acquired
before the first session. The patient was then admitted for the sec-
ond session the following day, after a new CT check‐up. The proce-
dure is repeated the following week for the third and fourth
sessions, with new MRI and CT images. OAR and target volumes are
contoured in accordance with the EMBRACE protocol. The treat-
ment planning system (TPS) used is Brachyvision‐Eclipse (Varian
Medical System Inc., Palo Alto, CA, USA). The mean time from initia-
tion of IMRT to the end of eBT was 52.5 days (49–58 days), and the
time between the end of IMRT and the end of eBT was 10.6 days
(7–15 days) (Table 2). The calculations are compared retrospectively
with those for Ir192 sources and for each of the eight patients, with
two plans per patient, giving a total of 32 different plans (16 for eBT
and 16 for Ir192).
Planning was performed after a CT study (3‐mm slice thickness)
and T2‐weighted MRI study (5‐mm slice thickness). Both sets of
images were registered.
CT images are used to reconstruct the applicators appropriately;
MRI is used to contour the target volumes and the OAR.
The high‐risk clinical target volume (HR‐CTV) and the intermedi-
ate‐risk clinical target volume (IR‐CTV) are contoured, and the blad-
der, rectum, and sigmoid colon as OAR following the
recommendations of GEC‐ESTRO.28
After the medical physicist reconstructs the applicators and pre-
pares the plan according to the dosimetric requirements of the
EMBRACE protocol10 (Tables 3 and 4), the radiation oncologist
approves it, and if appropriate, the patient is treated. Subsequently,
an additional plan is drawn up for treatment with Ir192 source in
order to compare both plans. The processing unit defined in the TPS
for this purpose is Gammamed Plus with GammaMed Plus HDR
source 0.9 mm (Varian Medical System Inc., Palo Alto, CA, USA).
The calculation algorithm is TG‐43, with specific parameters for
the Axxent device.29
As for HR‐CTV and IR‐CTV, the values of the dose were deter-
mined to 90% (D90) and 98% (D98). HR‐CTV values are the same in
TAB L E 5 Comparison of dosimetric parameters for Axxent eBx and Ir‐192 HDR.
EBRT (IMRT)
Dose per fraction: 2 Gy
No fractions 23
Total dose: 46 Gy
BT (eBx or Ir‐192)
Dose per fraction: 7 Gy
No fractions 4
Total dose: 28 Gy
Vol HR‐CTV: 16.6cc
(10.1–38.7)
Dose per fraction (Gy)
Axxent‐eBx Ir‐192
Mean (Gy) SD (Gy) %PD Range (Gy) Range(%PD) Mean (Gy) SD (Gy) %PD Range (Gy) Range(%PD)
Target
HR‐CTV D98 7 0.7 100% 6.3–7.8 89–111% 7.1 0.8 101% 6.3–8.3 89–119%
D90 8.5 0.9 121% 7.6–10.0 108–142% 8.4 0.8 120% 7.6–10 108–143%
IR‐CTV D98 4 0.9 57% 3.0–5.4 42–76% 4.1 0.8 59% 3.4–5.3 48–76%
D90 4.9 1.0 70% 3.7–6.5 53–93% 5 0.9 71% 4.1–6.4 58–91%
Organs at risk
Bladder D2cc 4.4 0.8 63% 3.9–6.1 55–87% 4.6 0.8 66% 4.1–6.3 59–90%
D1cc 4.9 0.8 70% 4.3–6.7 61–96% 5.1 0.8 73% 4.5–6.9 64–99%
D0.1cc 5.9 0.9 84% 5.4–8.1 77–115% 6 0.9 86% 5.5–8.2 79–117%
Rectum D2cc 2.1 0.7 30% 1.3–3.5 19–49% 2.6 0.7 37% 1.9–3.9 26–56%
D1cc 2.5 0.8 36% 1.5–3.8 21–54% 3 0.8 43% 2.1–4.1 30–59%
D0.1cc 3.5 1.0 50% 1.9–4.4 26–63% 3.9 1.0 56% 2.5–4.9 36–70%
Sigmoid D2cc 3.8 0.7 54% 3.1–5.2 44–74% 4 0.7 57% 3.3–5.3 47–76%
D1cc 4.4 0.9 63% 3.7–6.2 52–88% 4.6 0.9 66% 3.9–6.4 55–91%
D0.1cc 6 1.4 86% 4.6–8.5 65–121% 6.2 1.4 89% 4.8–8.7 69–124%
D98, D90: Dose to the 98% or 90% of the HR‐CTV or IR‐CTV volume in Gy.
D2cc, D1cc, D0.1cc: Doses to the volume of 2 cc, 1 cc, or 0.1 cc in Gy and in %PD (percentage of prescribed dose).
SD, standard deviation; Vol HR‐CTV, Volume of HR‐CTV, average, and range; HR‐CTV, high‐risk clinical target volume; IR‐CTV, intermediate‐risk clinical
target volume.
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the two treatment plans in each case, since the same normalization
is applied throughout planning. We also determined V150 and V200,
both of the HR‐CTV and of total tissue (sum of tumor tissue and
healthy tissue), which receive 150% and 200% of the prescribed
dose.
As for the OAR, the parameters are the same as those recom-
mended in the EMBRACE protocol, and they are determined for all
OAR of interest in the study, namely, bladder, rectum, and sigmoid
colon. The parameters compared are D2cc (maximum dose, 2 cc),
D1cc, and D0.1cc; toxicity is evaluated according to the parameters
of the Radiation Therapy Oncology Group (RTOG).30
3 | RESULTS
Patients were followed up for a median of 13.4 months (2–
28 months). Patients planned with eBT received a lower dose in the
OARs than those planned with Ir192. The differences in the energy
of both irradiation methods constitute the isodose lines that lead to
the dose differences in the OARs (Fig. 2).
In the bladder, the average dose parameters for all the treat-
ments compared (eBT vs Ir192) were 63% of the prescribed dose vs
66% for D2cc, 70% vs 73% for D1cc, and 84% vs 86% for D0.1cc.
The differences were more remarkable in the rectum (30% vs 37%
for D2cc, 32.9% vs 36% for D1cc, and 50% vs 56% for D0.1cc) and
in the sigmoid colon (D2cc, 54% vs 57%; D1cc, 63% vs 66%; and
D0.1cc, 86% vs 89%) with an average HR‐CTV volume of 16.6 cc
(Table 5).
By applying these data and the t test, we see that the difference
is significant for cases of D2cc and D1cc of the rectum (P < 0.05)
(Fig. 3).
Although D90 and D98 for HR‐CTV were the values used to
standardize the plans, we did observe a small difference in the cov-
erage of IR‐CTV—57% of the prescribed dose for eBT vs 59% for
HDR‐BT—although both were above the objective set by EMBRACE
(>46%, Tables 3 and 4). In addition to the differences in the IR‐CTV
coverage percentage, it is useful to observe the differences in dose
equivalent to 2 Gy (EQD2), taking into account the contribution of
EBRT and the part of eBT or Ir192 in each case (Table 6). V150 and
V200 for HR‐CTV were greater for the cases calculated with Axxent
than for those calculated with Ir192, although the difference was
very small owing to the volume of the tumors treated. In addition,
even though tissue volumes that received 150% and 200% of the
dose prescribed were included (Table 7), given the low energy of
eBT compared to Ir192 also observed an increase in the dose in the
vaginal wall in contact with the surface of the ovoids of 13% on
average, although no cases of acute mucositis were observed. Of
the eight patients treated at our center, only one had grade 2 acute
toxicity (RTOG) (Table 8). One month after treatment, vaginal toxic-
ity had disappeared. Rectal toxicity and urinal toxicity were minimal
(Table 8). To date, no patients have experienced recurrence of their
disease.
4 | DISCUSSION
We obtained acceptable results after the first 28 months (mean fol-
low‐up, 13.4; range, 2–28 months) using the Axxent eBT device for
treatment of cervical cancer with EBRT and chemotherapy, thus indi-
cating that this option is a good alternative in BT.
The dose prescribed in each eBT treatment was administered
without taking into account the fact that the mean beam energy
was much lower than in Ir192 (26 keV vs 355 keV) and, therefore,
without taking into account the differences in the relative radiobio-
logical effectiveness (RBE) expected for low‐energy radiation.31,32
One clinical study showed that reducing the dose prescribed for
treatment of nodular and superficial basal cell carcinoma using eBT
and based on a different RBE reduced control of the tumor from
95% to 90%, thus demonstrating better control for the standard pre-
scription.33
In our study, we did not modify treatment owing to differences
in RBE with respect to Ir192 because of the good results achieved
with treatment administered to the endometrium26 and the contra-
dictory results reported in several published studies. Modification of
F I G . 3 . Box and Whisker Plot: D1cc and D2cc of rectum.
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the prescribed dose continues to be controversial in low‐energy
cases.34
We can achieve the same coverage of the cervix as during plan-
ning when Ir192 is used in all of the cases presented and the dose
to OAR can be reduced, even though V150 and V200 of the plan-
ning target volume increase very slightly. This could have led to an
increase in the number of cases of acute mucositis in the study pop-
ulation; however, the toxicity results, together with the reduced
dose administered to OAR, lead us to conclude that eBT is a good
alternative to treatment with Ir192 in cases of cervical cancer.
In their study of 10 patients, Mobit et al.24 evaluated dosimetric
differences and similarities between treatment plans generated with
the eBT source of Axxent and Ir92 for tandem applicators and
ovoids. The authors reported a difference between the two
approaches (eBT vs Ir192) for D2cc in the bladder (43.9% vs 58.7%
of the prescribed dose), in the rectum (54.9% vs 60.9%), and in the
sigmoid colon (44.1% vs 56%). However, in this case, patients were
treated with Ir192, and the eBT plans were calculated prospectively.
As for the calculation method used, it is recommended to con-
sider tissue composition and to perform the calculations based on
Monte Carlo models.35 Our calculations were based on TG‐43, which
was modified for eBT,29,36 with no correction for heterogeneity,
since this was the algorithm used in our TPS and in many other hos-
pitals, for which our results will prove useful.
The sample of patients selected only included tumors with no
parametrial extension so as not to require insertion of interstitial
needles during treatment. Since this modality is not yet available in
the Axxent model, patients requiring interstitial needles were
referred to another center.
Results for the healthy tissue volume that received high doses
are slightly higher in the case of eBT, where the tissue irradiated
with 150% of the prescribed dose corresponds to 132% of the HR‐
CTV volume, compared with 124% in cases planned with Ir192. For
tissue irradiated with 200%, these values are 67% vs 63% (Table 7).
The differences do not represent an excessive volume in each indi-
vidual case and, more importantly, do not correspond to an increase
in the number of cases of mucositis.
The dose in OAR is slightly lower in the case of eBT, and cases
of toxicity associated with doses in OAR are minimal (Table 8).
We did not encounter problems of overdosing in bone, because
we used low energies.20 However, overdosing should be avoided in
order to reduce the number of fractions and thus prevent this prob-
lem from arising. We believe that the scheme proposed by
EMBRACE is adequate in this respect.
Both dosimetry requirements of the EMBRACE protocol were
fulfilled for both types of treatment, although D0.1cc in the sigmoid
colon would be above tolerance for Ir192. However, as stated
above, this does not lead to more cases of mucositis. These results,
TAB L E 6 EQD2 for Axxent and Ir‐192. BT and EBRT (IMRT) obtained adding doses according to linear quadratic model.
AXXENT Ir‐192
EQD2(Gy) EQD2(Gy)
BT BT + IMRT %PD %SD BT BT + IMRT %PD %SD
α/β = 10Gy
Target
HR‐CTV Prescription dose. 39.7 85.7 100% 39.7 85.7 100%
D98 39.7 85.7 100% 9% 40.5 86.5 101% 14%
D90 52.4 98.4 121% 13% 51.5 97.5 120% 17%
IR‐CTV D98 18.7 68.7 57% 13% 19.3 65.3 59% 8%
D90 24.3 70.3 70% 14% 25.0 71.0 71% 10%
α/β = 3Gy
Organs at risk
Bladder D2cc 26.6 72.6 64% 9% 28.0 74.0 66% 9%
D1cc 30.0 76.0 69% 10% 33.0 79.0 73% 10%
D0.1cc 41.4 87.4 84% 12% 43.2 89.2 86% 12%
Rectum D2cc 6.1 52.1 23% 4% 11.6 57.6 37% 5%
D1cc 9.0 55.0 31% 5% 14.4 60.4 43% 6%
D0.1cc 14.6 60.6 43% 7% 21.5 67.5 56% 8%
Sigmoid D2cc 19.8 65.8 53% 8% 22.4 68.4 57% 8%
D1cc 23.8 69.8 59% 9% 28.0 74.0 66% 9%
D0.1cc 38.1 84.1 79% 12% 45.6 91.6 89% 13%
α/β = 10 Gy for target and 3 Gy for OAR according to EMBRACE.
EQD2, Equivalent dose to 2 Gy per fraction in EBRT; %PD, Percentage of Prescribed Dose; %SD, Standard Deviation of %PD; IMRT, intensity modu-
lated radiation therapy; BT, brachytherapy; HR‐CTV, high‐risk clinical target volume; IR‐CTV, intermediate‐risk clinical target volume.
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together with the absence of relapses to date, allow us to be opti-
mistic with respect to determining a good eBT‐based alternative to
this treatment approach, although longer follow‐up is necessary
before we can confirm our findings. In addition, we must await the
findings of other groups.
5 | CONCLUSION
Treatment with eBT represents a huge advantage in centers with no
HDR device, although more clinical results, results for local control,
and results based on a longer follow‐up are necessary. Our data are
based on only eight patients, thus reducing the importance of the
conclusion. Nevertheless, they are a promising beginning for treat-
ment of cervical cancer with electronic brachytherapy. The doses in
the OARs are lower with eBT, although the difference is not signifi-
cant in the bladder or sigmoid colon. They are significant, however,
for the D2cc and D1cc parameters in the rectum. The broad experi-
ence accumulated over the years with Ir192 treatments makes it the
reference for cervical cancer, eBT could be an alternative in cases
where treatment with Ir 192 is not available, as long as the results
obtained continue to be satisfactory.
The eBT device is a useful addition in centers with an HDR
device. Its mobility and versatility mean that it can be used as a
complementary facility to treat cervical cancer and for intraoperative
radiotherapy in breast cancer, in skin cancer, and in postoperative
treatment of endometrial cancer.26
In areas with a high incidence of cervical cancer and few Ir192‐
based HDR devices, eBT could be a good alternative for patients who
live far from a major hospital. In addition, given that treatment does
not require a bunker for administration and the device is easily trans-
ported, this option is much more economically viable than others.
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